Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Ardelyx's phase III trial of tenapanor meets primary endpoint

Feb. 15, 2017

Ionis Pharmaceuticals earns milestone from Bayer for advancing antisense drugs

Feb. 15, 2017

Anti-VEGF-B agent CSL-346 developed to treat diabetic kidney disease

Feb. 14, 2017

First patient dosed in Angion Biomedica's phase II study of BB3

Feb. 1, 2017

Lundbeck discovers novel PDE9 inhibitors

Jan. 26, 2017

Resverlogix reports results from phase I trial of apabetalone in severe kidney impairment

Jan. 24, 2017

Roche divulges novel DDR1 inhibitors

Jan. 20, 2017

Chongqing University reports PDE5A inhibitors

Jan. 13, 2017

Kissei Pharmaceutical describes TRPM8 antagonists

Jan. 12, 2017

Phase IIa study of SER-150 in diabetic nephropathy reaches primary endpoint

Jan. 5, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...